Treatment of acromegaly with megavoltage radiation therapy

David A. Pistenma, Don R. Goffinet, Malcolm A. Bagshaw, John W. Hanbery, J. R. Eltringham

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

From 1956 to 1972, 22 previously untreated patients with acromegaly received high dose (average equivalent dose 5700 rad in 5.66 weeks) megavohage (4-4.8 MeV) irradiation at Stanford, 3 post-operatively and 19 as the only intended treatment. Two patients required surgical intervention for deteriorating vision 3 months after initial treatment by irradiation alone, but received no additional treatment. Four patients (18.2%) have died 5-11 years after treatment, 2 of suicide and 2 of cerebrovascular accidents. Eight patients (36%) experienced improvement of their soft tissue acromegalic features whereas the remainder, including the 4 who died, had shown no progression of disease with follow-up ranging from 20 months to almost 18 years. Radiation-induced hormone deficiencies were limited to a need for thyroid in one of 11 patients initially euthyroid and a subsequent need for testosterone in 2 of 6 men approximately 4 years after treatment. Considerations in the treatment of patients with acromegaly and plans for a limited controlled study at Stanford are presented.

Original languageEnglish (US)
Pages (from-to)885-893
Number of pages9
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume1
Issue number9-10
DOIs
StatePublished - 1976

Fingerprint

Acromegaly
radiation therapy
Radiotherapy
Therapeutics
dosage
irradiation
hormones
accidents
progressions
Suicide
Disease Progression
Testosterone
Thyroid Gland
Stroke
Hormones
Radiation
radiation

Keywords

  • Acromegaly
  • Megavoltage irradiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Pistenma, D. A., Goffinet, D. R., Bagshaw, M. A., Hanbery, J. W., & Eltringham, J. R. (1976). Treatment of acromegaly with megavoltage radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 1(9-10), 885-893. https://doi.org/10.1016/0360-3016(76)90113-9

Treatment of acromegaly with megavoltage radiation therapy. / Pistenma, David A.; Goffinet, Don R.; Bagshaw, Malcolm A.; Hanbery, John W.; Eltringham, J. R.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 1, No. 9-10, 1976, p. 885-893.

Research output: Contribution to journalArticle

Pistenma, DA, Goffinet, DR, Bagshaw, MA, Hanbery, JW & Eltringham, JR 1976, 'Treatment of acromegaly with megavoltage radiation therapy', International Journal of Radiation Oncology, Biology, Physics, vol. 1, no. 9-10, pp. 885-893. https://doi.org/10.1016/0360-3016(76)90113-9
Pistenma, David A. ; Goffinet, Don R. ; Bagshaw, Malcolm A. ; Hanbery, John W. ; Eltringham, J. R. / Treatment of acromegaly with megavoltage radiation therapy. In: International Journal of Radiation Oncology, Biology, Physics. 1976 ; Vol. 1, No. 9-10. pp. 885-893.
@article{24ce4bf38e0d4dca91137882406bd694,
title = "Treatment of acromegaly with megavoltage radiation therapy",
abstract = "From 1956 to 1972, 22 previously untreated patients with acromegaly received high dose (average equivalent dose 5700 rad in 5.66 weeks) megavohage (4-4.8 MeV) irradiation at Stanford, 3 post-operatively and 19 as the only intended treatment. Two patients required surgical intervention for deteriorating vision 3 months after initial treatment by irradiation alone, but received no additional treatment. Four patients (18.2{\%}) have died 5-11 years after treatment, 2 of suicide and 2 of cerebrovascular accidents. Eight patients (36{\%}) experienced improvement of their soft tissue acromegalic features whereas the remainder, including the 4 who died, had shown no progression of disease with follow-up ranging from 20 months to almost 18 years. Radiation-induced hormone deficiencies were limited to a need for thyroid in one of 11 patients initially euthyroid and a subsequent need for testosterone in 2 of 6 men approximately 4 years after treatment. Considerations in the treatment of patients with acromegaly and plans for a limited controlled study at Stanford are presented.",
keywords = "Acromegaly, Megavoltage irradiation",
author = "Pistenma, {David A.} and Goffinet, {Don R.} and Bagshaw, {Malcolm A.} and Hanbery, {John W.} and Eltringham, {J. R.}",
year = "1976",
doi = "10.1016/0360-3016(76)90113-9",
language = "English (US)",
volume = "1",
pages = "885--893",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "9-10",

}

TY - JOUR

T1 - Treatment of acromegaly with megavoltage radiation therapy

AU - Pistenma, David A.

AU - Goffinet, Don R.

AU - Bagshaw, Malcolm A.

AU - Hanbery, John W.

AU - Eltringham, J. R.

PY - 1976

Y1 - 1976

N2 - From 1956 to 1972, 22 previously untreated patients with acromegaly received high dose (average equivalent dose 5700 rad in 5.66 weeks) megavohage (4-4.8 MeV) irradiation at Stanford, 3 post-operatively and 19 as the only intended treatment. Two patients required surgical intervention for deteriorating vision 3 months after initial treatment by irradiation alone, but received no additional treatment. Four patients (18.2%) have died 5-11 years after treatment, 2 of suicide and 2 of cerebrovascular accidents. Eight patients (36%) experienced improvement of their soft tissue acromegalic features whereas the remainder, including the 4 who died, had shown no progression of disease with follow-up ranging from 20 months to almost 18 years. Radiation-induced hormone deficiencies were limited to a need for thyroid in one of 11 patients initially euthyroid and a subsequent need for testosterone in 2 of 6 men approximately 4 years after treatment. Considerations in the treatment of patients with acromegaly and plans for a limited controlled study at Stanford are presented.

AB - From 1956 to 1972, 22 previously untreated patients with acromegaly received high dose (average equivalent dose 5700 rad in 5.66 weeks) megavohage (4-4.8 MeV) irradiation at Stanford, 3 post-operatively and 19 as the only intended treatment. Two patients required surgical intervention for deteriorating vision 3 months after initial treatment by irradiation alone, but received no additional treatment. Four patients (18.2%) have died 5-11 years after treatment, 2 of suicide and 2 of cerebrovascular accidents. Eight patients (36%) experienced improvement of their soft tissue acromegalic features whereas the remainder, including the 4 who died, had shown no progression of disease with follow-up ranging from 20 months to almost 18 years. Radiation-induced hormone deficiencies were limited to a need for thyroid in one of 11 patients initially euthyroid and a subsequent need for testosterone in 2 of 6 men approximately 4 years after treatment. Considerations in the treatment of patients with acromegaly and plans for a limited controlled study at Stanford are presented.

KW - Acromegaly

KW - Megavoltage irradiation

UR - http://www.scopus.com/inward/record.url?scp=0017193019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017193019&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(76)90113-9

DO - 10.1016/0360-3016(76)90113-9

M3 - Article

VL - 1

SP - 885

EP - 893

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 9-10

ER -